Cellectar Biosciences Patent Application for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles Published by USPTO

May 20, 2016

Cellectar Biosciences Satisfies All Nasdaq Listing Criteria

May 16, 2016

Cellectar Biosciences Announces First Quarter 2016 Financial Results

May 12, 2016

Cellectar Biosciences to Host Conference Call on May 12, 2016 to Report First Quarter 2016 Financial Results and Provide a Corporate Performance Update

May 4, 2016

Cellectar Biosciences Announces Successful Completion of $8 Million Public Offering

Apr 20, 2016

Cellectar Biosciences Announces Pricing of $7,000,000 Public Offering

Apr 15, 2016

Cellectar Biosciences Receives Positive NASDAQ Listing Determination

Apr 7, 2016

Cellectar Biosciences Announces Year End 2015 Financial Results

Mar 10, 2016

Cellectar Biosciences to Present at the 28th Annual Roth Capital Conference

Mar 8, 2016

Cellectar Biosciences to Host Conference Call on March 10 to Report Year End 2015 Financials, Corporate Performance and 2016 Objectives

Mar 7, 2016